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Abstract  
Elucidating how cannabinoids affect brain function is instrumental for the development of 
therapeutic tools aiming to mitigate ‘on target’ side effects of cannabinoid based therapies. A 
single treatment with the cannabinoid receptor agonist, WIN 55,212-2, disrupts recognition 
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55,212-2 (1mg/kg) alters recognition memory and impacts on brain metabolism and functional 
connectivity. We show that chronic, intermittent treatment with WIN 55,212-2 disrupts 
recognition memory (Novel Object Recognition Test) without affecting locomotion and anxiety-
like behaviour (Open Field and Elevated Plus Maze). Through 14C-2-deoxyglucose functional 
brain imaging we show that chronic, intermittent WIN 55,212-2 exposure induces 
hypometabolism in the hippocampal dorsal subiculum and in the mediodorsal nucleus of the 
thalamus, two brain regions directly involved in recognition memory. In addition, WIN 55,212-
2 exposure induces hypometabolism in the habenula with a contrasting hypermetabolism in the 
globus pallidus. Through the application of the Partial Least Squares Regression (PLSR) 
algorithm to the brain imaging data, we observed that prolonged WIN 55,212-2 administration 
alters functional connectivity in brain networks that underlie recognition memory, including that 
between the hippocampus and prefrontal cortex, the thalamus and prefrontal cortex, and 
between the hippocampus and the perirhinal cortex. In addition, our results support disturbed 
lateral habenula and serotonin system functional connectivity following WIN 55,212-2 
exposure. Overall, this study provides new insight into the functional mechanisms underlying 
the impact of chronic cannabinoid exposure on memory and highlights the serotonin system as a 
particularly vulnerable target.  
 




14C-2-DG   14C-2-deoxyglucose  
AcbC  Nucleus Accumbens Core 
AcbSh  Nucleus Accumbens Shell 
AM  Anteromedial Thalamus 
aPrL  Anterior Prelimbic Cortex 
aRT  Reticular Thalamus 
AV  Anteroventral Thalamus 
BLA  Basolateral Amygdala 
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CB1R  Cannabinoid receptor 1 
Cg1  Cingulate Cortex 
ChWin  Chronic WIN 55,212-2  
ChVeh  Chronic VEH  
CoA  Central Amygdala 
DH CA1  Dorsal Hippocampus, CA1 
DH CA2  Dorsal Hippocampus, CA2 
DH DG Dorsal Hippocampus, Dentate Gyrus 
DH Mol Dorsal Hippocampus, Molecular Layer 
DLO  Dorsolateral Orbital Cortex 
DLST  Dorsolateral Striatum 
DMSO   Dimethylsulfoxide 
DR  Dorsal Raphe 
DSub  Dorsal Subiculum 
ENT  Entorhinal Cortex 
EPMT   Elevated plus maze test 
fMRI Functional magnetic resonance imaging 
FRA  Frontal Association Area 
GP  Globus Pallidus 
Hab  Habenula 
HDB Horizontal Limb of Diagonal Band of Broca 
IL  Infralimbic Cortex 
Ins  Insular Cortex 
I.P  Intraperitoneal injection 
LCGU Local cerebral glucose utilization 
LO  Lateral Orbital Cortex 
LS  Lateral Septum 
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MD   Medio Dorsal Thalamus 
MeA  Medial Amygdala 
MG  Medial Geniculate 
MO  Medial Orbital Cortex 
mPrL  Medial Prelimbic Cortex 
MR  Medial Raphe  
MS  Medial Septum 
MTL  Medial temporal lobe 
NORT  Novel object recognition test 
NPI  Novelty preference index 
OFT  Open field test 
Piri  Piriform Cortex 
PD  Post-natal days  
PRh  Perirhinal Cortex 
PLSR  Partial least squares regression 
RSc  Retrosplenial Cortex 
S1  Somatosensory Cortex 
SNC  Substancia Nigra pars Compacta 
SNR  Substancia Nigra pars Reticulata 
UR  Uptake ratio 
VDB Ventral Limb of Diagonal Band of Broca 
VH CA1  Ventral Hippocampus, CA1 
VH CA3  Ventral Hippocampus, CA3 
VH DG Ventral Hippocampus, Dentate Gyrus 
VH LMol Ventral Hippocampus, Molecular Layer 
VL  Ventrolateral Thalamus 
VM  Ventromedial Thalamus 
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VTA  Ventral Tegmental Area 
WIN55,212-2 (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-
benzoxazin-6-yl]-1-naphthyl-methanone mesylate;   
Introduction 
 Heavy or regular cannabis abuse, generally defined as daily or almost-daily use over a 
prolonged period of time, has been linked to cognitive dysfunction (Abush and Akirav, 2012) 
and increased risk of developing psychiatric symptoms, including schizophrenia-spectrum 
disorders (Andréasson et al., 1987, Hall and Degenhardt, 2009), acute psychosis and mania 
(Khan and Akella, 2009), and an amotivational syndrome (Tunving, 1987; Fujiwara, 2001; 
Ozaki and Wada, 2001). In addition, cannabis-based medicines are increasingly being used to 
treat several diseases such as epilepsy (Maa and Figi, 2014), chronic pain (Carter et al., 2015), 
multiple sclerosis (Fitzpatrick and Downer, 2016), and neurodegenerative diseases (Fagan and 
Campbell, 2014), but the potential for negative side effects has not been well characterised. 
Understanding the effects of chronic cannabinoid exposure upon brain and synaptic function 
opens a window into the development of therapeutic tools that could counteract the “on target” 
side-effects  associated with chronic use of cannabis and cannabinoid-based medicines 
(Copeland et al., 2013; Lovelace et al., 2015). 
Cannabinoid receptor 1 (CB1R) mediate the characteristic psychoactive effects of 
exogenous cannabinoids and the synaptic actions of endocannabinoids (Kano et al., 2009). One 
immediate consequence of cannabis consumption is an impairment in memory consolidation, 
seen in both humans (Ranganathan and D’Souza, 2006; Borgelt et al., 2013) and laboratory 
animals (Clarke et al., 2008; Kano et al., 2009; Sousa et al., 2011; Mouro et al., 2017). 
Cannabinoid-mediated disruptions in learning and memory may be related to reported 
impairments in long-term potentiation (LTP) at glutamatergic synapses (Terranova et al., 1995; 
Stella et a., 1997; Misner and Sullivan, 1999; Wang et al., 2016; Silva-Cruz et al., 2017), 
detrimental modifications in fast/slow wave oscillations, known to be modulated by GABAergic 
interneurons (Freund et al., 2003), and altered activity in septal-hippocampal monoaminergic 
and cholinergic pathways, known to regulate cortical plasticity and activity (Miller and 
Branconnier, 1983; Gessa et al. 1998; Sulivan 2000; Redmer et al. 2003; Khakpai et al. 2012).  
Studies in humans, using functional magnetic resonance imaging (fMRI), have shown 
that chronic cannabis users display significant alterations in functional connectivity in brain 
networks relevant to self-awareness (Pujol et al. 2014), working memory (Cousijn et al. 2013) 
and recognition memory (Riba et al. 2015) which may be linked with functional differences in 
structures of the medial temporal lobe (MTL) and prefrontal cortex (PFC) (Riba et al. 2015). In 
a recent study, it was also shown that chronic marijuana use leads to increased functional 
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innervate the orbitofrontal cortex (Filbey et al., 2014). However, chronic consumption studies in 
humans can be contaminated by confounding variables, such as lifestyle factors or mixed drug 
use. 
The present work was designed to elucidate the impact of chronic, intermittent 
cannabinoid exposure on brain metabolism, functional brain connectivity and recognition 
memory. We carry out three different analysis: first, we evaluated recognition memory in the 
Novel Object Recognition Test (NORT); secondly, we studied brain metabolic activity in these 
animals using 14-C-2-deoxyglucose (14C-2-DG) functional brain imaging and finally, we 
characterized alterations in brain network functional connectivity through the application of the 
Partial Least Squares Regression (PLSR) algorithm to the 14C-2-DG brain imaging data. We 
found out that adult mice chronically exposed to WIN 55,212-2 displayed impaired recognition 
memory and differences in metabolic brain activity and dysfunctional connectivity in circuits 
that underlie memory processing, thus providing new insights into the functional mechanisms 




Adult (8-12 weeks old) male C57BL/6 mice (IMSR Cat# CRL:27, 
RRID:IMSR_CRL:27) (Charles River, Barcelona, Spain) were used. Animals were housed in a 
temperature (22/24ºC) and humidity (45-65%) regulated room with a 14/10-hour light/dark 
cycle (07:00-21:00) with ad libitum access to food and water. Animal behaviour experiments 
were conducted during the light phase at around the same time each day (10:00). All 
experimentation followed the European Community Guidelines (Directive 2010/63/EU) and the 
Portuguese law (DL 113/2013) for Animal Care for Research Purposes, and were approved by 
the “Instituto de Medicina Molecular” Internal Committee and the Portuguese Animal Ethics 
Committee –Direcção Geral de Veterinária). The experimental protocol was not preregistered. 
Animals were habituated to the presence of the investigator and handled for 5-days before 
testing. A total of 40 mice were used, 20 were treated with WIN 55,212-2 and 20 were receiving 
the vehicle only. All animals were used for behaviour analysis, which was performed in two 
series of 10 mice per drug condition, giving a total of 20 mice per condition. For connectivity 
analysis, 10 mice per condition were used. To determine whether an animal would be allocated 
to the control or experimental treatment group a pseudo-randomization procedure was 
employed. Animals were tagged and distributed in groups of 5 animals to each housing cage (8 
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condition (either control or chronic WIN 55,212-2). To do so, a number was attributed to each 
cage and randomly drawn. Drawn cage numbers were distributed sequentially to either the 
control or the experimental group (first drawn number allocated to control, the second drawn 
number attributed to experimental group, until all numbers have been drawn).  
Drugs 
WIN 55,212-2 (TOCRIS Bioscience, catalogue number 1038) was suspended in 
dimethylsulfoxide (DMSO, Sigma Aldrich, catalogue number D2650) at stock concentration of 
100mM, and stored at -20ºC.; appropriate dilutions of these solutions were made in saline (NaCl 
0.9%) before injection. The amount of DMSO present in the solutions used for intraperitoneal 
(i.p.) injections was less than 0.6µl per mouse, and control animals were injected with 
equivalent amounts of vehicle (2 ml/kg).  
 
Chronic WIN 55,212-2 Treatment Protocol  
WIN 55,212-2 was administered at a dose of 1mg/kg i.p., a dose known to affect 
recognition memory in the NORT without creating sedative or cataleptic effects that are 
associated with higher doses (Schneider and Koch, 2003; Baek et al. 2009; Mouro et al. 2017), 
over 30 days. Behavioural tests were carried out on the last seven days of treatment. The 
injections were performed around the same hour of the day (18:00 ± 1 hour), while behavioural 
tests were performed during the morning (10:00). Doing so, we avoided withdrawal symptoms 
(Maldonado, 2002; Lichtman and Martin, 2005; Solymosi and Köfalvi 2017), while minimizing 
acute effects of the drug during testing. In order to replicate a pattern of chronic intermittent 
cannabinoid exposure (Lamarque et al, 2001; Schneider and Koch, 2003) animals were treated 
for 5 consecutive days followed by two days without treatment (22 injections over 30 days). 
This protocol was designed to minimize the tolerance to WIN 55,212-2 that may develop during 
chronic continuous administration (see Maldonado, 2002; Hampson et al. 2003; Solymosi and 
Köfalvi 2017). For further detail on the treatment and experimental protocol see Figure 1.  
 
Novel Object Recognition Test (NORT) 
NORT was conducted in a wooden square open field arena (40 x 40 x 40 cm) as 
previously reported (Bailey and Crawley, 2009; Antunes and Biala, 2012). In brief, the test 
involved a habituation period (3 days), a training day and a test day. Before training, animals 
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and environmental conditions, for 20 minutes over 3 consecutive days. On the fourth day, after 
habituation, animals were placed inside the arena, facing away from the two identical objects 
(familiar objects) and allowed to freely explore the environment and objects for 5 minutes. After 
a retention interval of 24 hours, to test long-term memory (Clarke et al. 2008; Antunes and 
Biala, 2012), animals were placed inside the arena with one novel and one familiar object (test 
day). Animals were allowed to explore the objects for 5 minutes. The objects used in the 
training and test days were wooden dolls (7 cm height x 6 cm width). The role of the object, as 
either familiar or novel, was randomized as was the location of their presentation. To randomize 
the role of the object a blind experimenter was asked to randomly select one of the objects to be 
the novel object for the first animal. Then, for the following animals, the novel object was 
always permuted, to ensure that both objects were used as the novel object the same number of 
times in both the control and the experimental groups (for instance, if the object A was 
randomly selected for the trial of animal 1, then for animal 2 the novel object would be object B, 
for animal 3 the object would be again object A, and so on). Between every trial the arena and 
the objects were cleaned with 30% ethanol to erase any olfactory clues. The objects were 
secured to the bottom of the arena with Velcro, which could not be seen or touched by the 
animals, and were placed in opposite corners of the arena. Activity was recorded using the 
video-tracking software – SMART® (RRID:SCR_002852). To refine the results obtained by 
software measures, a post-analysis was conducted. In the post-analysis, the investigator was 
blind to the experimental condition. Exploratory behaviour was quantified as the amount of time 
(seconds) animals spent investigating each object (only direct approaches were considered; ≤ 1 
cm distance). The number of approaches that included sniffing the object, rearing towards the 
object or touching the object, were counted (Ennaceur and Delacour, 1988; Ennaceur, 2010; 
Antunes and Biala, 2012). Exploration of each object was quantified as the novelty preference 
index (NPI) - calculated as (B-A) / (B+A), where B corresponds to the time spent exploring the 
novel object and A the time spent exploring the familiar object, during the test phase of NORT. 
This index ranges from -1 to 1 (-1 = exclusive exploration of the familiar object; 0 = absence of 
discrimination between novel and familiar objects, i.e. equal time exploring both objects, and 1 
= exploration of the novel object only).We defined full immobility during the test stage of 
NORT as an a priori exclusion criterion, by which no animals were excluded from analysis. 
However, data from one animal on the control group was eliminated by post-analysis since it 
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Open field test (OFT) and Elevated Plus Maze (EPM) 
 Anxiety-like and locomotor behaviour were analysed in the OFT and EPM. Behaviour 
in the OFT was analysed before the NORT. The OFT was used to assess individual behaviour 
when animals were placed in a novel environment (Wilson et al., 1976), as well as anxiety 
(Careau et al., 2012). Since locomotor activity can impact exploratory drive (Broadhurst, 1957, 
1958; Stanford, 2007), it was important to ascertain that animals did not display significant 
differences in locomotor activity. The OFT took place in the same arena as that used for the 
NORT (square open field arena: 40 x 40 x 40 cm) and activity was recorded during the first time 
that animals had contact with the environment, i.e., on the first 5 minutes of the first day of 
NOR habituation phase (see schematics on figure 1). To quantify behaviour, the percentage of 
time spent in the central zone of the arena was used as an indicator of anxiety, as previously 
described (Mouro et al. 2017). Mean velocity and distance moved were quantified to compare 
locomotor abilities between the experimental groups. Activity was recorded and analysed using 
the video-tracking software – SMART® (RRID:SCR_002852). The reference point used by the 
software to determine the position of the animal was the center of the mouse dorsum, as done 
previously in our Institute (Batalha et al. 2013, Coelho et al. 2014, Mouro et al 2017). 
Environmental conditions and animal manipulation procedures were kept as similar as possible 
between animals. 
Anxiety-like behaviour was also assessed in the EPM. Immediately after being tested in 
the NORT during the test day (see schematics on figure 1), animals were placed in a maze 
shaped like a plus sign composed by two open arms with no walls (5 x 29 cm) and two closed 
arms (5 x 29 x 15 cm) arranged perpendicularly and elevated 50 cm above the floor (Mouro et 
al. 2017). Animals were placed on the center of the maze, facing an open arm, and allowed to 
freely explore the maze during 5 minutes. The total time spent in open arms was used as a 
measure of anxiety-like behaviour (Pellow et al. 1985, Coelho et al., 2014, Mouro et al. 2017).  
 
14C-2-D-deoxyglucose functional brain imaging 
Local cerebral glucose utilization (LCGU) was determined after the final WIN 55,212-2 
(or vehicle) treatment (n=10 per group, at day 31 for half of the controls and half of the test 
animals, at day 32 for the remaining animals), in accordance with previously published 
protocols (Dawson et al., 2012; 2015). In brief, mice were injected i.p. with 4.625 MBq/Kg of 
2-deoxy-D-[14C]glucose diluted in physiological saline (American Radiolabeled Chemicals Inc., 
USA, catalogue number ARC 0111A, dose volume of 2.5 ml/kg). After the injection animals 
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sacrificed by cervical dislocation and subsequently decapitated. A terminal blood sample was 
collected from the neck by torso inversion, to determine circulating glucose levels (Accu-Chek 
Aviva Blood Glucose Monitor). The brain was dissected out and immediately frozen in 
isopentane (-40ºC) and stored at -80ºC until sectioning. Blood samples were centrifuged to 
separate the plasma for determination of plasma 2-deoxy-D-[14C]glucose concentration by 
liquid scintillation analysis (supplemental material, Table S1).  
Brains were coronally sectioned in a cryostat (-20ºC) at 20 µm. Three consecutive 
sections were retained from every 60 µm and dried rapidly onto slide covers on a hot plate 
(70ºC). Autoradiograms were obtained by placing these sections, along with pre-calibrated 14C-
standards (39-1069 nCi/g tissue equivalents; American Radiolabelled Chemicals Inc. USA, 
catalogue number ARC 0146R) to high resolution autoradiographic film (Carestream Kodak 
Biomax MR, Sigma-Aldrich, UK, catalogue number Z358460-50EA) for 7 days, after which 
they were developed in accordance with the manufacturer’s instructions. Autoradiographic 
images were analysed by computer-based images analysis (MCID/M5) (RRID:SCR_014278). 
The local isotope concentration for each brain region of interest (RoI) was obtained directly 
from the optical density of autoradiographic images relative to that of co-exposed 14C-standards. 
Forty-nine anatomically distinct RoI were measured with reference to a stereotactic mouse brain 
atlas (Paxinos and Franklin, 2001) (RRID:SCR_007127). LCGU in each RoI was obtained by 
comparing the ratio of 14C in each RoI to the 14C concentration in the whole brain of the same 
animal, referred to as the 14C-2-DG uptake ratio (14C-2-DG UR). The whole brain average 14C 
concentration was determined as the average 14C concentration across all sections in which a 
RoI was measured. No animals were excluded from this data set. 
 
Functional Brain Connectivity  
Regional functional connectivity was analysed in control (saline-treated) and WIN 
55,212-2-treated mice. To elucidate the impact of chronic WIN 55,212-2 exposure on regional 
functional connectivity we applied the Partial Least Squares Regression (PLSR) algorithm (pls 
package in R, https://CRAN.R-project.org/package=pls, Mevik & Wehrens, 2007), to 
characterize statistically significant differences in the functional connectivity of defined “seed 
regions” to all the other RoI’s analysed. In our analysis these seed regions were chosen on the 
basis of the overt differences in LCGU seen following chronic WIN 55,212-2 treatment (Figure 
4). Thus, the chosen seed brain regions in our analysis were the dorsal subiculum of the ventral 
hippocampus (DSub), the mediodorsal thalamic nucleus (MD), the habenula (Hab) and the 
globus pallidus (GP). The application of the PLSR algorithm to functional 14C-2-DG imaging 
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connectivity between each seed RoI and all other RoI measured was defined by the variable 
importance to the projection (VIP) statistic gained from PLSR analysis. A significant functional 
connection between brain regions was considered to exist if the 95% confidence interval (CI) of 
the VIP statistic exceeded 0.8, denoting a considerable contribution of the explanatory variable 
(RoI) to the dependent variable (seed region) in PLSR analysis. The SD and CI of the VIP 
statistic were estimated by jack-knifing. The significance of WIN 55,212-2 induced alterations 
in the VIP statistic were determined by t-test with post-hoc Bonferroni correction for multiple 
comparisons. WIN 55,212-2 induced alterations in functional connectivity on this basis were 
thus defined as being significant increases or reductions in functional connectivity (where the 
value of the VIP statistic is significantly altered between the groups but the 95% CI of the VIP 
statistic exceeds the 0.8 threshold in both experimental groups), or significantly lost or newly 
gained functional connectivity (WIN 55,212-2-treated animals significantly different from 
controls and the 95% CI of the VIP statistic exceeds the 0.8 threshold in only one of the 
experimental groups) .  
 
Statistical Analysis  
Data are expressed as means ± SEM. All data sets were tested for normality and 
analysed in Graphpad Prism 6 software (RRID:SCR_002798) or R (version 3.4.4, 
http://www.r-project.org, RRID: SCR_001905). A test for outliers was performed using the 
Graphpad Outlier Calculator. NORT data were analysed using two-tailed, paired or unpaired 
Student’s t tests, as appropriate for each condition and as indicated in the figure legends. Overt 
alterations in LCGU were statistically analysed by Student’s t test, with discrete RoI treated as 
independent variables, as previously justified (Kelly and McCulloch, 1985). Significance was 
set at p<0.05 throughout.  
 
Results 
Chronic, intermittent WIN-55,212-2 administration disrupts recognition memory 
Chronic, intermittent exposure to the cannabinoid agonist WIN 55,212-2 disrupted 
recognition memory evaluated in the NORT. In the training phase, control animals (vehicle 
treated) and animals treated chronically with WIN 55,212-2 explored the two identical objects 
for a similar amount of time (Figure 2, panel A). However, on the test day, while control 
animals showed a significant preference for the novel as compared to the familiar object 
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seen when analysing the novelty preference index (NPI) with control animals showing a 
significant preference for the novel object during the test phase (P < 0.05, n =19), while WIN 
55,212-2 treated animals did not (Figure 2, panel B). Importantly, we found that there was no 
significant difference in the total time of object exploration between control or WIN 55,212-2 
treated mice, during either the training or test phase (Figure 2, panels C and D). 
The NPI scores obtained in the present work were not significantly different from zero, 
being similar to those previously reported by us using the same NORT paradigm in mice of the 
same age during acute WIN 55,212-2 administration (Mouro et al., 2017). This indicates that the 
treatment schedule used in the present work does not result in tolerance with regards to 
recognition memory. Once confirmed this was then taken as a positive control to proceed for the 
assessment of the influence of WIN 55,212-2 upon brain metabolism and functional brain 
connectivity, to elucidated the functional changes underlying this deficit.  
 
Chronic, intermittent WIN-55,212-2 administration does not alter locomotor behaviour or 
anxiety-like behaviour 
Anxiety-like behaviour and locomotor abilities were measured before, after and during 
the memory test, using respectively, the OF test, the EPM and by measuring the total time of 
object exploration during the test phase of the NORT. We found no evidence to suggest that 
chronic WIN 55,212-2 administration significantly impacted on locomotor activity or anxiety 
like behaviour (Figure 2, panel C and D, Figure 3).  
 
Chronic, intermittent WIN 55,212-2 administration alters LCGU  
Chronic, intermittent WIN 55,212-2 administration induced both increases and 
decreases in LCGU on a brain region dependent basis. WIN 55,212-2 treated mice showed 
marked hypometabolism in the dorsal subiculum of the ventral hippocampus (DSub), the 
thalamic mediodorsal nucleus (MD) and in the habenula (Hab) (P < 0.05, n = 10). By contrast, 
WIN 55,212-2 treated animals showed significant hypermetabolism in only one of the brain 
regions analysed, the Globus Pallidus (GP) (P < 0.05, n = 10). These results support altered 
function in the basal ganglia-thalamic-hippocampal circuits (Figure 4). Interestingly, when 
measuring LCGU on three different amygdala regions, there were no statistically significant 
differences between control and experimental groups. Thus, this data supports the results 
obtained in the behaviour tests which showed no significant differences in anxiety-like 
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brain imaging data are shown in the supplemental material (Table S2). Blood glucose and level 
of 14C-2-DG in the plasma were not significantly altered in control and WIN 55,212-2 treated 
animals (Table S1).  
 
Regional Functional Connectivity 
We analysed the functional connectivity of four “seed” regions, defined as those where 
we had identified a significant impact of WIN 55,212-2 treatment on LCGU (DSub, MD, Hab, 
GP). Analysis by means of PLSR algorithm, revealed significant modifications in functional 
connectivity in the mice that had received WIN 55,212-2 (Figure 5).  
For the DSub of the ventral hippocampus, in control animals this region was 
significantly connected to multiple subfields of the PFC, selected other ventral hippocampal 
subfields, and to the serotonergic raphé (dorsal raphé, DR; median raphé, MR; supplemental 
Table S3). In animals treated with WIN 55,212-2, functional connectivity of the DSub was 
significantly altered. Specifically, significant decreases (anterior prelimbic, aPrL; medial orbital 
MO; and medial prelimbic, mPrL), and lost (infralimbic, IL) connectivity with multiple PFC 
regions was seen in animals treated chronically with WIN 55,212-2. By contrast, chronic WIN 
55,212-2 administration resulted in new abnormal functional connectivity between the DSub of 
the ventral hippocampus and subfields of the dorsal hippocampus (CA1, CA2. In addition, 
functional connectivity of the DSub to other subfields in the ventral hippocampus was 
significantly enhanced (Mol, CA3) or gained (DG) in WIN 55,212-2 treated animals. This 
suggests that the local connectivity of the ventral hippocampus DSub to other hippocampal 
subfields was significantly increased as a result of chronic WIN 55,212-2 administration. In 
addition, functional connectivity of the DSub to the perirhinal (PRh) cortex was abnormally 
gained in response to chronic WIN 55,212-2 treatment. Furthermore, the DSub gained new 
functional connectivity to discrete thalamic nuclei (anteroventral, AV; mediodorsal, MD) and to 
the serotonergic MR following chronic WIN-55,212-2 administration.  
 
 In control animals the Hab was functionally connected with several PFC subfields and 
several striatal, hippocampal and amygdala regions (supplemental Table S4). Following chronic 
WIN 55,212-2 treatment the functional connectivity of the Hab was significantly altered. On 
one hand, the Hab lost functional connectivity with multiple PFC subfields (FRA; dorsolateral 
orbital cortex, DLO; lateral orbital cortex, LO and IL) and showed significantly lost (substantia 
nigra pars compacta, SNC) and decreased connectivity (dorsolateral striatum, DLST; GP and 
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55,212-2 treatment provoked abnormal gains in connectivity between the Hab and subfields of 
the nucleus accumbens (core, AcbC; shell, AcbSh), with the serotonergic system (dorsal raphé, 
DR).    
In control animals the MD thalamic nucleus was significantly functionally connected to 
multiple subfields of the prefrontal cortex (PFC), other cortical regions and other thalamic 
nuclei (supplemental material, Table S5). The functional connectivity of the MD was 
significantly altered in mice treated chronically with WIN 55,212-2. This included significantly 
lost (anteroventral nucleus, AV) or decreased (anteromedial nucleus, AM; anterior reticular 
thalamus, aRT) connectivity to other thalamic nuclei, and cortical regions (frontal association 
cortex, FRA; insular cortex, Ins). By contrast, chronic WIN 55,212-2 treatment resulted in new, 
abnormal functional connectivity between the MD and multiple subfields of the 
septum/diagonal band of Broca (medial septum, MS; lateral septum, LS; ventral limb of the 
diagonal band of broca, VDB). 
 Finally, in control animals the GP was functionally connected to numerous regions of 
the septum/diagonal band of Broca, and to striatal and cortical regions (supplemental Table S6). 
As a consequence of chronic WIN 55,212-2 treatment the functional connectivity of the GP was 
significantly modified. The GP significantly lost functional connectivity with several regions of 
the septum/diagonal band of Broca (medial septum, MS; ventral limb diagonal band of Broca, 
VDB; horizontal limb diagonal band of Broca, HDB) and to the striatum (DLST and VMST). 
By contrast, the GP gained abnormal new connectivity with PFC (DLO, mPrl and cingulate 
cortex, Cg1) and to the serotonergic raphe (MR and DR) following chronic, intermittent WIN 




In this work we demonstrated that mice chronically exposed to the non-selective 
cannabinoid receptor agonist, WIN 55,212-2, displayed disrupted cerebral metabolism and 
abnormal functional connectivity in the cortico-thalamic-hippocampal circuits that underlie 
recognition memory. This includes compromised perirhinal-hippocampus-prefrontal cortex and 
thalamo-prefrontal functional connectivity. In parallel, we observed deficits in recognition 
memory as a consequence of chronic WIN 55,212-2 administration without signs of altered 
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CB1Rs on synapses inhibit glutamatergic and GABAergic transmission, modulate 
different forms of synaptic plasticity, and control neural oscillations that support behaviour and 
diverse cognitive functions, including learning and memory (Hajos et al. 2000; Piomelli et al., 
2003, Albayram et al. 2016; Kano et al., 2009; Araque et al., 2017; Lupica et al., 2017). 
Altogether, previous data also suggest that endo- and exo- cannabinoids may induce the 
functional reconfiguration of neuronal and brain networks to impact on memory processing, and 
we now specifically addressed this possibility.  
Object recognition learning and memory is a process involving multiple items, the 
contextual clues surrounding them and the temporal order in each they are presented. Effective 
recognition memory depends on functional interactions within a circuit comprised by the 
perirhinal cortex (Bussey et al. 2000; Warburton and Brown, 2010), the hippocampus (Brown 
and Aggleton, 2001; Barker and Warburton 2011), the medial prefrontal cortex (O’Neil et al. 
2012) and the mediodorsal nucleus of the thalamus (Mitchell et al. 2005; Warburton and Brown, 
2015). In this work we report deficits on recognition memory following chronic, intermittent 
WIN 55,212-2 treatment as assessed by the NORT. Data from the behavioural test served as a 
positive confirmation for the results obtained from the brain imaging and functional 
connectivity experiments , discussed below. We found that chronic, intermittent WIN 55-212-2 
administration significantly impacts on the function and connectivity of the hippocampal dorsal 
subiculum (DSub, Figure 5), in line with previous suggestions that the subiculum is involved in 
recognition memory (Chang and Huerta, 2012). The subiculum is a primary output structure of 
the hippocampus and receives direct projections from other brain regions critical for recognition 
memory, including the perirhinal cortex (Amaral et al., 2007). Monosynaptic and reciprocal 
connections  between the subiculum and the perirhinal and the postrhinal cortices exist (Witter 
et al., 2000), implicating the subiculum in a short functional loop with cortical areas known to 
be crucial for recognition memory (Warburton and Brown, 2010). Our study revealed that 
chronic, intermittent WIN 55,212-2 treatment induced a pattern of irregular and dysfunctional 
connectivity between the dorsal subiculum and virtually every other subfield of the 
hippocampus (CA1, CA2, CA3, ML and DG; Figure 5). Furthermore, chronic, intermittent WIN 
55,212-2 treatment impaired connectivity between the dorsal subiculum and several subfields of 
the prefrontal cortex, another structure directly implicated in recognition memory (Riba et al. 
2015).  
We also found widespread evidence for functional dysconnectivity of the mediodorsal 
(MD) thalamic nuclei as a consequence of WIN 55,212-2 administration, which could also 
contribute to the deficits in recognition memory seen in these animals. Indeed, there is building 
evidence supporting a cortico-thalamic-hippocampal network, including the MD, that underlies 
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relay between the perirhinal and the medial prefrontal cortex (Parker and Gaffan, 1998; 
Warburton and Brown, 2015). The mediodorsal thalamic nucleus directly projects to the 
hippocampus and to the prefrontal cortex. Lesions in this thalamic nucleus result in recognition 
memory deficits (Parker et al., 1997), replicating deficits related with lesions of the medial 
temporal lobe (Warburton and Brown, 2015). In addition, it has been previously shown that 
disconnection of the mediodorsal thalamic nucleus from the medial temporal cortex impairs 
object-in-place and temporal order performance (Cross et al., 2012).  
The habenula is an important anatomical hub involved in a diverse range of behaviours 
including reward processing, reward prediction error, memory and the stress response 
(Naamboodiri et al., 2016). The habenula receives direct projections from the prefrontal cortex 
and the basal ganglia (globus pallidus, Hikosaka, et al., 2008), regions that show reduced 
functional connectivity to the habenula after chronic, intermittent WIN 55,212-2 administration 
(Figure 4). The habenula also sends direct projections to dopamine rich brain regions including 
the ventral tegmental area (VTA) and substantia nigra pars compacta (SNC, Hikosaka, et al., 
2008). Remarkably, the functional connectivity of the habenula to these regions is also lost in 
animals treated chronically with WIN 55,212-2. Moreover, the functional connectivity of the 
habenula to other components of the mesolimbic system, including the nucleus accumbens, is 
also significantly altered by chronic WIN 55,212-2 treated animals. These effects may relate to 
the amotivation syndrome (Tunving et al., 1987) and reward processing deficits (Fujiwara, 
2001; Friemel et al., 2014) seen as a result of cannabinoid exposure. By contrast, the functional 
connectivity of the habenula to the serotonergic raphe, to which the habenula directly projects, 
is abnormally enhanced by chronic WIN 55,212-2 administration. This suggests that chronic 
cannabinoid exposure may impact both dopaminergic and serotonergic system function by 
impacting, in part, on the functional connectivity of the habenula.  
Altered serotonin system function as a result of chronic, intermittent WIN 55,212-2 
administration, is also supported by broader evidence of altered raphé nuclei functional 
connectivity, being evident to each of the seed brain regions analysed. A number of previous 
studies have found that chronic cannabinoid exposure alters the functioning of the serotonin 
system, including the induction of altered serotonin levels (Sagredo et al., 2006) and serotonin 
receptor activity (Esteban & Garcia-Sevilla, 2011; Darmani et al., 2001; Hill et al., 2006; 
Frankin et al., 2013; Moranta et al., 2009). Moreover, the role of the serotonin system in 
recognition memory is firmly established (Zhang et al., 2013; 2015) suggesting that the 
disruption of serotonin system connectivity may be one of the key mechanisms by which 
chronic, intermittent WIN 55,212-2 exposure impairs recognition memory. This possibility 
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serotonin system may represent a therapeutic strategy to restore memory deficits as a 
consequence of chronic cannabinoid exposure. 
Cannabinoid intake induces more severe behavioural deficits in pubertal rats than in 
mature animals (Schneider and Koch 2002; Schneider et al., 2008). Indeed, short-term 
recognition memory impairments (30 min retention time in NORT) can persist beyond 
cannabinoid exposure if the exposure occurs during the pubertal period (Schneider and Koch 
2002; Schneider et al., 2008), but not if the exposure occurs only during adulthood (Schneider 
and Koch, 2003) or even if it occurs only during the pre-pubertal period (Schneider et al., 2005). 
However, as we herein show, cannabinoid exposure in adulthood does induce alterations in 
brain metabolism and connectivity, and these alterations are accompanied by significant 
recognition memory impairments over longer retention intervals (24 hours). In addition, the 
present evidence showing that functional connectivity between the thalamus and prefrontal 
cortex is affected by cannabinoid exposure is in line with previous findings that cannabinoids 
can exacerbate deficits induced by prefrontal cortex lesions (Schneider and Koch 2005; 2007). 
The exact pharmacological identification of the receptor influenced by the cannabinoid 
compound used in the present work is outside its objective. However, there is evidence that 
supports the possibility of the presently described actions of WIN 55,212-2 being mediated 
through CB1R. WIN 55-212,2 is one of the most commonly used cannabinomimetics to study 
the role of the CB1R and the CB2R (Solymosi and Köfalvi, 2017), showing similar preference 
for activating both receptors (Pertwee et al. 2010). On the other hand, evidence has consistently 
shown that WIN 55,212-2 has no effect upon G protein-coupled receptor 55 (GPR55) (Johns et 
al. 2007; Ryberg et al. 2007; Pertwee et al. 2010; Solymosi and Köfalvi, 2017). We previously 
showed that the CB1R selective antagonist (AM 251) abolished the impact of acute WIN 
55,212-2 administration on recognition memory, which was evaluated with the same NORT 
paradigm and using mice of the same age as used in this study (Mouro et al., 2017), supporting  
involvement of CB1R. There is, in fact, a broad range of evidence supporting the involvement of 
CB1R in memory deficits (Clarke et al 2008, Suenaga and Ichitani, 2008, Wise et al. 2010), 
while CB2R agonists do not seem to affect recognition memory (Clarke et al. 2008). Regarding 
modifications of brain metabolism following cannabinoid administration, evidence shows that 
CB1R agonists lead to decreases in glucose uptake (Duarte et al. 2012; Miederer et al 2017) and 
mitochondrial respiration (Bernard et al. 2012).  
In conclusion, we herein demonstrated that prolonged, intermittent exposure of adult 
mice to the non-selective cannabinoid receptor agonist WIN 55,212-2, induces alterations in 
metabolic brain activity in selected brain regions, alters their functional connectivity, and 
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directly involved in recognition memory, and for the habenula and raphé nuclei. These data give 
new insight into the mechanisms by which chronic cannabinoid exposure impacts on behaviour 
and cognition, and highlight the value of considering cannabinoid actions at the systems-level 
perspective.  
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Figures 
Figure 1. Scheme depicting the treatment schedule and overall experimental protocol. 
Over 30 consecutive days mice were treated with 22 intraperitoneal (i.p.) injections with WIN 
55,212-2 or vehicle control. Behavioural tests were performed between day 22 and 26; as 
indicated in the inset. The habituation phase of NORT was initiated on day 22, simultaneously 
with the OFT. The habituation continued on the days 23 and 24. The training phase of NORT 
was performed on day 25. On day 26 the test phase of NORT was performed. Immediately after 
the NORT animals were placed in the EPM to assess anxiety-like behaviour. Subsequently, 24 
hours after the final WIN 55,212-2 treatment, animals underwent the 14C-2-deoxyglucose brain 
imaging protocol. From the initial 40 animals, one animal of the control group was excluded by 
post-analysis (outlier, P<0.05); thus 19 control and 20 WIN 55,212-2 treated mice were used in 
the behavioural assays and 10 control and 10 WIN 55,212-2 treated mice were used in the 14C-
2-deoxyglucose brain imaging study.  
 
Figure 2. Chronic, intermittent WIN 55, 212-2 treatment impairs recognition memory in 
the NORT. Panel A. Data is represented as % of exploration time. A denotes familiar object 1, 
A’ denotes familiar object 2, B denotes the novel object. – On the training day the % of time 
spent exploring each of the familiar objects did not differ between control and WIN 55,212-2 
treated animals (P > 0.05, paired Student’s T test). On the test day, control animals explored the 
novel object significantly more than the familiar object (****P < 0.0001, paired Student’s T 
test). However, animals treated chronically with WIN 55,212-2 spent a similar amount of time 
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of time spent with A and B).  Panel B – The Novelty Preference Index (NPI) is significantly 
decreased in WIN 55-212-2 treated animals as compared to controls (**P < 0.01, unpaired 
Student’s T test). A novelty index of zero represents absence of discrimination between objects 
(see Methods for details). The NPI of WIN55,212-2 treated mice was not significantly different 
from zero (P > 0.05, unpaired Student’s t test), whereas in control mice the NPI was 
significantly different (P < 0.0001) from zero. Panels C and D – Total time of object 
exploration (TTE) during the training and test phase of NORT was not significantly different 
between VEH and WIN treated animals (P > 0.05, unpaired Student’s T test). An a posteriori 
Power Analysis for NORT data was performed using G*power 3.1 software; considering a 
mean of 0.201 of preference for the novelty in control and 0.050 for drug treated animals 
(pooled sd (0.15), there is a 87.5% correct chance of correctly rejecting the null hypothesis (no 
differences on the T test), using 19 animals in the control group and 20 animals in the 
experimental group from a total of 39 animals. 
 
Figure 3. | Chronic, Intermittent WIN55, 212-2 treatment does not impact on locomotor 
activity or anxiety-like behaviour. Panel A and B – Locomotor abilities were assessed in the 
open field test (OFT) (panels A and B), performed during the first habituation day of the NORT. 
Chronic WIN, 55,212-2 treatment did not significantly alter the total distance travelled (panel 
A) or velocity (panel B) in comparison to vehicle-treated controls (P > 0.05, unpaired Student’s 
T test). Panels C and D –Anxiety-like behaviour was assessed at two time-points: before the 
NORT in the OFT, by evaluating the percentage of time spent in the central zone (panel C), and 
after NORT test, in the EPM test (panel D) by evaluating the percentage of time spent in the 
open arms of the maze. In both tests, there were no significant differences between WIN 
55,212-2 treated animals and saline-treated controls (P > 0.05, unpaired Student’s t test).  
 
Figure 4. | Chronic, intermittent WIN 55,212-2 administration induces localised increases 
and decreases in local cerebral glucose utilisation.  Panel A – Chronic, intermittent WIN 
55,212-2 administration induced significantly decreased cerebral metabolism in the dorsal 
subiculum (DS), Mediodorsal thalamus (MD), and Habenula (Hab) and increased metabolism in 
the Globus Pallidus (GP). By contrast, cerebral metabolism in the amygdala nuclei (Basolateral, 
BLA; Central, CeA; Medial, MeA) was not significantly altered in WIN 55,212 treated animals. 
| Data shown as the 14C-2-DG uptake ratio obtained for each RoI. *denotes P<0.05 significant 
difference from control (unpaired Student’s t-test). Panel B – representative false colour 
autoradiograms at the level of the dorsal and ventral hippocampus showing altered cerebral 
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warmer colours (red/orange) and lower rates of metabolism by cooler colours (blue/green). Full 
data are shown in the supplemental table S2. 
 
Figure 5. | Chronic, intermittent WIN 55,212 treatment alters functional connectivity in 
neural circuits underpinning recognition memory. Panel A | Heatmap showing how chronic, 
intermittent treatment with WIN 55,212-2 induced modifications in the functional connectivity 
of “seed” brain regions (DSub, MD, Hab and GP). Dark red denotes significantly gained 
connectivity while light red represents significantly increased connectivity. Dark blue represents 
significantly lost connectivity whereas light blue denotes significantly decreased connectivity. 
Significant gains, losses, increases and decreases in connectivity were determined by statistical 
comparison of the VIP statistic (unpaired Student’s T test with Bonferroni post-hoc correction) 
determined PSLR, with significance level set at P < 0.05. Full data for each 'seed' region are 
shown in the Supplementary Tables S3–S6. Panel B | Brain images showing the anatomical 
localization of brain regions with significant increased/gained connectivity to the “seed” regions 
(DSub, Hab, MD and GP). Yellow represents the anatomical localization of the “seed” brain 





























































This article is protected by copyright. All rights reserved. 
 
